To the Editor.—I read with great interest the article on the use of famciclovir in recurrent genital herpes by Dr Sacks and colleagues.1 Interestingly, no mention was made on the number of clinical episodes (the development of vesicular and ulcerative lesions) of genital herpes aborted by famciclovir, although the incidence of aborted clinical episodes was mentioned as a parameter in the "Methods" section. This well-designed study1 should have been able to detect any effect, since treatment was patient initiated and patients were selected to have prodomal symptoms. Abortive viral shedding was found. However, it is not clear whether the ability of famciclovir to abort clinical episodes was studied and found to be insignificant vs placebo or simply was not studied.